Ziopharm Inc., The University of Texas M.D. Anderson Cancer Center, Texas A&M University deal

Ziopharm received a global exclusive license from the universities to a class of organic arsenicals to treat hematologic and solid cancers. Ziopharm expects to begin Phase I studies of ZIO-101 in the...